25/05/2026
Introducing SITA-MET 500 & SITA-MET 1000
Advanced Dual-Action Glycemic Management for Type 2 Diabetes
At Lative Life Science Pvt. Ltd., we are committed to delivering high-quality pharmaceutical solutions that support better patient outcomes.
SITA-MET combines the proven efficacy of Sitagliptin + Metformin to help healthcare professionals achieve effective glycemic control through complementary mechanisms of action.
✅ Supports fasting and postprandial blood glucose control
✅ Improves insulin sensitivity
✅ Helps reduce HbA1c levels
✅ Well-tolerated with enhanced patient compliance
✅ Trusted combination therapy for Type 2 Diabetes Mellitus
Available Strengths:
🔹 SITA-MET 500 (Sitagliptin 50 mg + Metformin 500 mg)
🔹 SITA-MET 1000 (Sitagliptin 50 mg + Metformin 1000 mg)
💡 Indication:
For the management of Type 2 Diabetes Mellitus in adults when diet, exercise, and monotherapy do not provide adequate glycemic control.
At Lative Life Science, we continue to focus on innovation, quality, and patient-centric healthcare solutions.
📞 Contact Us
📱 +91 87803 01812
📧 [email protected]
🌐 www.lativelifescience.com
Lative Life Science Pvt. Ltd.
Trusted Quality. Healthier Tomorrow.
